Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.33), $0.04 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $90.3 million versus the consensus estimate of $86.93 million.

"The Exact Sciences team delivered strong growth to start the year by remaining relentlessly focused on our core priorities. By increasing awareness and adoption of Cologuard, we are making strides toward our mission of playing a role in the eradication of colon cancer," said Kevin Conroy, chairman and CEO of Exact Sciences. "The success of Cologuard also positions us to develop tests that facilitate the early, accurate detection of other forms of cancer."

GUIDANCE:

Exact Sciences continues to see FY2018 revenue of $420-430 million, versus the consensus of $431.7 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.